Skip to main contentAI and Advanced
/
LOTUSEYE · NSEMarket ticker unavailable · configure an authorised index feed
LO
NSE · Equity shares · Healthcare Facilities4.00 · 3.60%
Lotus Eye Hospital and Institute LOTUSEYE
NSE:INR 115
BSE:INR 120
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for LOTUSEYE
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 111
Day rangeINR 110.01 — INR 115.59
52-week rangeINR 97.59 — INR 147
Volume10,389
Market cap248.55
P/E2,455.5
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)53.71
Net Income (INR Cr)0.08
Rev Growth (5 Year %)10.66
EPS Growth (5 Year %)-44.42
P/E Ratio2,455.5
Book Value28.81
EPS0.04
Price/BV3.99Computed
Research path: Interpret Lotus Eye Hospital and Institute's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
LOTUSEYELotus Eye Hospital and Institute1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 82.6 | 69.57 | 66.63 |
| Cash Equivalents | 3.83 | 4.15 | 2.58 |
| Other Liabilities Total | 0.11 | Not available | 0.3 |
| Long Term Debt | 10.17 | 0.12 | Not available |
| Common Stock Total | 20.8 | 20.8 | 20.8 |
| Other Current Assets Total | 2.51 | 2.27 | 0.11 |
| Total Assets | 82.6 | 69.57 | 66.63 |
| Current Portof LT Debt/Capital Leases | 2.82 | 1.4 | 0.42 |
| Total Equity | 60.14 | 60 | 59.41 |
| Long Term Investments | 2.55 | 2.39 | Not available |
| Retained Earnings(Accumulated Deficit) | 39.34 | 39.2 | 13.57 |
| Total Common Shares Outstanding | 2.08 | 2.08 | 2.08 |
| Tangible Book Valueper Share Common Eq | 28.81 | 28.79 | 28.53 |
| Total Liabilities | 22.46 | 9.57 | 7.22 |
| Total Debt | 15.83 | 3.55 | 1.11 |
| Cashand Short Term Investments | 3.83 | 4.15 | 6.93 |
| Total Receivables Net | 1.21 | 1.32 | 1.48 |
| Accounts Receivable-Trade Net | 1.21 | 1.32 | 1.26 |
| Property/Plant/Equipment Total-Net | 65.68 | 53.94 | 48.65 |
| Total Current Liabilities | 9.34 | 7.42 | 6.23 |
| Total Inventory | 3.83 | 3.83 | 4.98 |
| Accounts Payable | 3.25 | 3.36 | 3.46 |
| Other Currentliabilities Total | 3.27 | 2.66 | 0.91 |
| Total Long Term Debt | 13.01 | 2.15 | 0.69 |
| Intangibles Net | 0.23 | 0.13 | 0.07 |
| Other Long Term Assets Total | 2.77 | 1.54 | 2.05 |
| Total Current Assets | 11.37 | 11.57 | 14.02 |
| Capital Lease Obligations | 2.84 | 2.03 | 0.69 |
| Notes Payable/Short Term Debt | Not available | 0 | 0 |
| Accumulated Depreciation Total | Not available | Not available | -48.37 |
| Accrued Expenses | Not available | Not available | 1.44 |
| Other Equity Total | Not available | Not available | -0.1 |
| Prepaid Expenses | Not available | Not available | 0.51 |
| Additional Paid-In Capital | Not available | Not available | 25.14 |
| Cash | Not available | Not available | 0.07 |
| Property/Plant/Equipment Total-Gross | Not available | Not available | 96.95 |
| Short Term Investments | Not available | Not available | 4.28 |
| Note Receivable-Long Term | Not available | Not available | 1.84 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %108.83
Margins
Operating Margin 12m-0.68
Operating Margin 5y Avg4.93
Net Profit Margin 12m0.15
Net Profit Margin 5y4.55
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio4.63
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk54.57
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Apollo Hospitals Enterprise | INR 8,905.9 | 1.28 L | 64.93 | — |
| Max Healthcare Institute | INR 1,087.45 | 1.06 L | 71.47 | — |
| Fortis Healthcare | INR 952.75 | 71,858.25 | 67.89 | — |
| Aster DM Healthcare | INR 800.05 | 41,211.42 | 102.55 | — |
| Narayana Hrudayalaya | INR 1,976.2 | 40,228.62 | 48.07 | — |
Shareholding
Ownership
- Promoter
- 40.14%
- FII
- 0.01%
- Other
- 59.86%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Lotus Eye Hospital Q4 FY26: Profitability Crisis Deepens Amid Revenue Growth - Markets MojoMarket news · 31 May 2026, 1:14 am
Lotus Eye Hospital Q4 FY26: Profitability Crisis Deepens Amid Revenue Growth Markets Mojo
Lotus Eye Hospital & Institute Ltd: Valuation Shifts Signal Elevated Risk Amid Price Attractiveness Decline - Markets MojoMarket news · 29 May 2026, 8:30 am
Lotus Eye Hospital & Institute Ltd: Valuation Shifts Signal Elevated Risk Amid Price Attractiveness Decline Markets Mojo
Lotus Eye Hospital & Institute Ltd Downgraded to Strong Sell Amid Deteriorating Quality Metrics - Markets MojoMarket news · 29 May 2026, 8:30 am
Lotus Eye Hospital & Institute Ltd Downgraded to Strong Sell Amid Deteriorating Quality Metrics Markets Mojo
Lotus Eye Hospital & Institute Ltd Downgraded to Strong Sell Amid Deteriorating Fundamentals - Markets MojoMarket news · 28 May 2026, 8:46 am
Lotus Eye Hospital & Institute Ltd Downgraded to Strong Sell Amid Deteriorating Fundamentals Markets Mojo
Lotus Eye Hospital & Institute Ltd is Rated Sell - Markets MojoMarket news · 27 May 2026, 4:43 pm
Lotus Eye Hospital & Institute Ltd is Rated Sell Markets Mojo
Lotus Eye Hospital FY26 profit falls 89% on higher costs - scanx.tradeMarket news · 27 May 2026, 12:30 pm
Lotus Eye Hospital FY26 profit falls 89% on higher costs scanx.trade
Corporate actions
Events
- board MeetingsAudited Results
- board MeetingsTo consider Voluntary Delisting of Shares.
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
Rusaka Markets Community
Discussion and sentiment for Lotus Eye Hospital and Institute
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Lotus Eye Hospital and Institute Limited is an India-based company, which is engaged in the business of healthcare activities. The Company is engaged in the field of ophthalmology (eye) and its related operations. It resolves a range of eye problems, such as refractive, cataract, cornea infections, ocular prosthesis, orbit and oculoplasty, glaucoma, keratoconus, computer vision syndrome, neuro ophthalmology, retinal disease/diabetic eye care, UVEA and ocular inflammation, zyoptix-ultimate, and binocular vision. The Company provides various treatments, suchas ReLEx SMILE, Touchfree Laser, Lasik Eye Surgery, Epi-LASIK, Intralase, Supracor, Robotic Femto Laser Cataract Surgery (LRCS), Phacoemulsification, Paediatric Eye Care and Squint Surgery, and Micro Incision Cataract Surgery (MICS). The Company operates in various locations, such as Sitra, Coimbatore; RS Puram, Coimbatore; Salem; Tirupur; Mettupalayam; Kochi; Mulanthuruthy; Saravanampatty, and Karur.
Company facts
- Industry
- Healthcare Facilities
- Sector
- Healthcare Facilities
- NSE Code
- LOTUSEYE
- BSE Code
- 532998
Questions
Stock FAQ
What is the symbol and ISIN of Lotus Eye Hospital and Institute?
Lotus Eye Hospital and Institute has the symbol LOTUSEYE and ISIN - INE947I01017.
What is the current price of Lotus Eye Hospital and Institute?
Lotus Eye Hospital and Institute is currently trading at INR 115.00.
What are the year high and year low of Lotus Eye Hospital and Institute?
Lotus Eye Hospital and Institute has a year high of INR 147.00 and a year low of INR 97.59.
What is the market capitalization of Lotus Eye Hospital and Institute?
Lotus Eye Hospital and Institute has a market capitalization of INR 248.55 crore.
What is the P/E ratio of Lotus Eye Hospital and Institute?
Lotus Eye Hospital and Institute has a P/E ratio of 2455.50.
What is the dividend yield of Lotus Eye Hospital and Institute?
Lotus Eye Hospital and Institute has a dividend yield of 0.00%.
How is the financial performance of Lotus Eye Hospital and Institute based on revenue, net income, and EPS?
Lotus Eye Hospital and Institute has revenue of INR 53.71 crore, net income of INR 0.08 crore, and EPS of INR 0.04.
What is the book value of Lotus Eye Hospital and Institute?
Lotus Eye Hospital and Institute has a book value of INR 28.81.
What is the debt-to-equity ratio of Lotus Eye Hospital and Institute?
Lotus Eye Hospital and Institute has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Lotus Eye Hospital and Institute?
Lotus Eye Hospital and Institute has a price-to-book ratio of 3.99 and a price-to-sales ratio of 4.63.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.